PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview. / Hasselbalch, Steen Gregers.

I: Ugeskrift for Laeger, Bind 177, Nr. 32, 03.08.2015, s. V11140610.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hasselbalch, SG 2015, 'PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview', Ugeskrift for Laeger, bind 177, nr. 32, s. V11140610.

APA

Hasselbalch, S. G. (2015). PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview. Ugeskrift for Laeger, 177(32), V11140610.

Vancouver

Hasselbalch SG. PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview. Ugeskrift for Laeger. 2015 aug. 3;177(32):V11140610.

Author

Hasselbalch, Steen Gregers. / PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview. I: Ugeskrift for Laeger. 2015 ; Bind 177, Nr. 32. s. V11140610.

Bibtex

@article{957c47b2ec894882a7c8032c693b1ae9,
title = "PET med amyloidligander b{\o}r ikke anvendesrutinem{\ae}ssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview",
abstract = "Recent diagnostic criteria for Alzheimer's disease incorporate biomarkers in order to increase the diagnostic accuracy. In a recent Cochrane review the ligand (11)C-PiB showed a high sensitivity, but low specificity for detecting patients with mild cognitive impairment who would develop Alzheimer's dementia. Given the evolution of Alzheimer pathology, these findings are not surprising. With current limited treatment options for MCI, (11)C-PiB-PET cannot be recommended for routine use in MCI and should be used only in selected cases where a positive scan will alter management.",
author = "Hasselbalch, {Steen Gregers}",
year = "2015",
month = aug,
day = "3",
language = "Dansk",
volume = "177",
pages = "V11140610",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "32",

}

RIS

TY - JOUR

T1 - PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview

AU - Hasselbalch, Steen Gregers

PY - 2015/8/3

Y1 - 2015/8/3

N2 - Recent diagnostic criteria for Alzheimer's disease incorporate biomarkers in order to increase the diagnostic accuracy. In a recent Cochrane review the ligand (11)C-PiB showed a high sensitivity, but low specificity for detecting patients with mild cognitive impairment who would develop Alzheimer's dementia. Given the evolution of Alzheimer pathology, these findings are not surprising. With current limited treatment options for MCI, (11)C-PiB-PET cannot be recommended for routine use in MCI and should be used only in selected cases where a positive scan will alter management.

AB - Recent diagnostic criteria for Alzheimer's disease incorporate biomarkers in order to increase the diagnostic accuracy. In a recent Cochrane review the ligand (11)C-PiB showed a high sensitivity, but low specificity for detecting patients with mild cognitive impairment who would develop Alzheimer's dementia. Given the evolution of Alzheimer pathology, these findings are not surprising. With current limited treatment options for MCI, (11)C-PiB-PET cannot be recommended for routine use in MCI and should be used only in selected cases where a positive scan will alter management.

M3 - Tidsskriftartikel

C2 - 26321582

VL - 177

SP - V11140610

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 32

ER -

ID: 162416555